Testing a new drug combo for HER2-positive digestive cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a combination of two drugs (sintilimab and pyrotinib) with or without chemotherapy for people with advanced digestive system cancers that have a specific marker called HER2. The goal is to see if this combination can shrink tumors or stop them from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a digestive system cancer (stomach, colorectal, liver, bile duct, or pancreatic cancer) that is HER2 positive and has spread or cannot be removed by surgery.
- You have either never had treatment for advanced cancer, or your previous first-line treatment stopped working or caused side effects.
- You have not had any treatment that targets HER2 before (like trastuzumab/Herceptin).
- You are in reasonably good health with normal organ function, no active infections, and no severe autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs (RC48, sintilimab, and SOX chemotherapy) for people with stomach or gastroesophageal junction cancer that cannot be removed by surgery, has not been treated before, and has a specific HER2 score (1+ or 2+). The goal is to shrink the tumor enough to possibly allow surgical removal.
This trial tests whether adding immunotherapy (sintilimab) to chemotherapy with or without lenvatinib helps people with HER2-negative stomach cancer that has spread. It compares three different treatment combinations to find the best option.
This trial tests a combination of three drugs—RC48 (a targeted therapy), sintilimab (an immunotherapy), and S-1 (a chemotherapy pill)—as a first treatment for advanced HER2-positive stomach cancer that has not been treated before. The goal is to see if this triple therapy works better than current options.
This trial tests a combination of two medicines (sintilimab and FOLFIRI) as a second option for people with advanced stomach cancer that no longer responds to first treatment. It aims to see if this combination can help control the cancer.
This study tests a new combination of targeted therapy (DP303c) with either a drug called simmitinib or a liposomal form of irinotecan for people with advanced stomach or GEJ cancer. The goal is to see if these combinations can shrink tumors or slow cancer growth.
This trial tests a combination of three drugs—sintilimab (an immunotherapy), nab-paclitaxel, and tegafur/gimeracil/oteracil—as a first treatment for stomach or gastroesophageal junction cancer that cannot be removed by surgery or has spread. The goal is to see if this combination helps shrink tumors and control the disease.
Hear when a new Advanced Digestive System Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.